Grant Pickering Sells 2,366 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 2,366 shares of Vaxcyte stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $103.89, for a total value of $245,803.74. Following the completion of the transaction, the chief executive officer now directly owns 137,398 shares in the company, valued at $14,274,278.22. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Grant Pickering also recently made the following trade(s):

• On Friday, November 1st, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $106.82, for a total value of $1,602,300.00.
• On Monday, October 7th, Grant Pickering sold 7,098 shares of Vaxcyte stock. The shares were sold at an average price of $109.21, for a total value of $775,172.58.
• On Friday, August 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $78.98, for a total value of $1,184,700.00.

Vaxcyte Stock Up 3.9 %

Shares of PCVX opened at $106.67 on Friday. The business’s 50 day moving average is $111.56 and its two-hundred day moving average is $87.23. Vaxcyte, Inc. has a 52-week low of $46.16 and a 52-week high of $121.06. The firm has a market cap of $13.30 billion, a price-to-earnings ratio of -23.19 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same period last year, the business earned ($0.91) earnings per share. On average, equities analysts expect that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors have recently made changes to their positions in PCVX. Riverview Trust Co bought a new stake in shares of Vaxcyte in the 3rd quarter valued at approximately $27,000. Fifth Third Bancorp bought a new stake in shares of Vaxcyte in the 2nd quarter valued at approximately $35,000. Blue Trust Inc. increased its holdings in shares of Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. J.Safra Asset Management Corp increased its holdings in shares of Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after acquiring an additional 526 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Vaxcyte in the 2nd quarter valued at approximately $70,000. 96.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on PCVX shares. Jefferies Financial Group boosted their price target on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Leerink Partners boosted their price target on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Mizuho boosted their price target on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Wednesday. Finally, Bank of America boosted their price target on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte presently has a consensus rating of “Buy” and an average price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.